

Please try another search
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Name | Age | Since | Title |
---|---|---|---|
Michelle Griffin | 57 | 2017 | Independent Director |
Stuart J. Swiedler | 66 | - | Member of the Scientific Advisory Board |
Marlene Haffner | 82 | - | Member of the Scientific Advisory Board |
Jason A. Amello | 55 | 2017 | Independent Director |
John M. Dunn | 71 | 2017 | Independent Director |
Thomas R. Fleming | - | - | Member of the Scientific Advisory Board |
Gerard T. Berry | - | - | Member of the Scientific Advisory Board |
Christopher Schelling | 47 | 2013 | Founder, President, CEO & Director |
Stephen J. Aselage | 72 | 2017 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review